Zimmer Biomet is expected to launch a robot soon that will compete with Stryker’s Mako Total Knee offering.
Stryker’s Mako Total Knee offering continues to gain traction and drive growth for the Kalamazoo, MI-based orthopedics company, but the company faces imminent competition in the space from Warsaw, IN-based Zimmer Biomet.
During Stryker’s third-quarter earnings call, CEO Kevin Lobo said the company is approaching 600 robots globally, and Lobo said he feels bullish about the future of robotic-assisted surgery.
Katherine Owen, vice president of strategy and investor relations at Stryker, said 37 Mako robots were installed globally during the third quarter, with 26 of those installs being in the United States. Comparing those numbers to the same quarter last year, Owen said 33 Mako robots were installed in the year-ago quarter, with 23 of those installs being in the U.S. market.
Owen also noted that more than 50% of robots installed during the recent quarter were in competitive accounts where Stryker either has no market share or share well below the company’s average number. Also, she said about 145 surgeons were trained on the Total Knee application, bringing the total number of surgeons trained since launch to about 1,350. As for procedure volume, Owen said roughly 11,300 Mako Total Knee procedures were performed with the robot during the third quarter in the United States.
Zimmer Biomet is currently waiting for FDA approval of its Rosa robotics knee application and in Australia, the first five procedures have already been done. CEO Bryan Hanson told analysts during Zimmer Biomet’s third-quarter earnings call to expect the full launch of that product in the back half of 2019.
Image Credit: Amanda Pedersen / MD+DI